Tag Archives: atrial fibrillation

Boehringer Ingelheim released two GLORIA™-AF Registry Program analyses examining the use of anticoagulant treatments for stroke prevention in patients with atrial fibrillation

For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA™-AF Registry Program Results presented at American College of Cardiology 64th Annual Scientific Session & … Read the full press release

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD (“Xention”), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway. … Read the full press release

Professor Paulus Kirchhof at ESC Congress 2013: Personalised management to close mortality gap for patients with atrial fibrillation (AF)

27-8-2013 — /EuropaWire/ — The fourth AFNET/EHRA consensus conference was convened to discuss how to identify the underlying main pathophysiologies of AF in individual patients so that more targeted therapies could be developed to close the mortality gap. Amsterdam, The Netherlands – Tuesday 27 … Read the full press release

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release